NGLY1

Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase · Q96IV0 · NGLY1 on Sugi Atlas →

1,349 patent compounds predicted against NGLY1, 1,039 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Dactinomycin (SCHEMBL3844)	1.00	1/20
Dactinomycin (SCHEMBL3845)	1.00	1/20
Dactinomycin (SCHEMBL6152)	1.00	1/20
Castanospermine (SCHEMBL61040)	1.00	1/20
Castanospermine (SCHEMBL764545)	1.00	1/20
Castanospermine (SCHEMBL2267745)	1.00	1/20
Castanospermine (SCHEMBL2434193)	1.00	1/20
Castanospermine (SCHEMBL4645261)	1.00	1/20
Dactinomycin (SCHEMBL6939686)	1.00	1/20
SCHEMBL7534675	1.00	1/20
Castanospermine (SCHEMBL10471084)	1.00	1/20
Castanospermine (SCHEMBL11921336)	1.00	1/20
Dactinomycin (SCHEMBL2790145)	0.99	1/20
SCHEMBL1650567	0.94	1/20
SCHEMBL12648475	0.93	1/20
Dactinomycin (SCHEMBL1073159)	0.92	1/20
Dactinomycin (SCHEMBL9983387)	0.88	1/20
Dactinomycin (SCHEMBL9125857)	0.87	1/20
SCHEMBL502640	0.86	1/20
SCHEMBL1873112	0.86	1/20

Clinical trials — most relevant to NGLY1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes	PHASE3	COMPLETED
Impact of Pantoprazole on 24-H Glycemic Control and on Post-prandial Glucose Excursion in Patients With Type 2 Diabetes	PHASE3	UNKNOWN
Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus	PHASE3	COMPLETED
Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.	PHASE3	COMPLETED
The Role of Islet GLP-1 in the Pathogenesis of Prediabetes	PHASE2	RECRUITING
Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus	PHASE2	COMPLETED
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes	PHASE2	RECRUITING
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus	PHASE2	COMPLETED
Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma	PHASE2	RECRUITING
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer	PHASE1/PHASE2	COMPLETED
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1	PHASE1/PHASE2	COMPLETED
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1	PHASE1	COMPLETED
Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus	PHASE1	COMPLETED
The Effect of VTC-G15 (a Pentapeptide Cleavage Product og GLP-1) on Whole Body Glucose Metabolism in Man	PHASE1	UNKNOWN
Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor	PHASE1	COMPLETED
Degradation of the Anorexic Hormone Peptide YY	EARLY_PHASE1	COMPLETED
LEAP2 Kinetics in Healthy Individuals	EARLY_PHASE1	COMPLETED
Ghrelin and Gastric Emptying in Children With Functional Dyspepsia	nan	COMPLETED
Pharmacodynamics of CNP During Growth Hormone Treatment	nan	COMPLETED
Effects of an Amino Acid-Based hGH Secretagogue on Triiodythyronine	nan	COMPLETED
Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing	nan	COMPLETED
Diagnostic and Prognostic Role of Troponin and Brain Natriuretic Peptide in Pediatric Patients With Cardiomyopathy in Correlation to Echocardiography Findings	nan	UNKNOWN
Ankle Brachial Index Versus Conventional Cardiac Risk Indices	nan	UNKNOWN
Neuronostatin - a Glucagonotropic Agent in Humans?	nan	COMPLETED
Prohepcidin, Inflammation and Iron Homeostasis in Hemodialysis Patients With Chronic Hepatitis C	nan	COMPLETED
Co-infusion of Neurotensin and GLP-1 Effects on Appetite and Food Intake.	nan	UNKNOWN
The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation	nan	UNKNOWN
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING
The PRO-SOma COla (PROSOCO) Study	nan	UNKNOWN
Diagnostic and Prognostic Value of Serial Procalcitonin (PCT) Measurements in Critically Ill Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NGLY1 binder may also engage these)

Protein	Name	Similarity
Q4R6F3	—	1.000	Q4R6F3 →
Q5ZJM3	—	1.000	Q5ZJM3 →
Q5XI55	—	1.000	Q5XI55 →
Q9JI78	—	1.000	Q9JI78 →
Q28YQ7	—	0.992	Q28YQ7 →
Q503I8	—	0.992	Q503I8 →
Q4KLT3	—	0.986	Q4KLT3 →
Q7KRR5	—	0.985	Q7KRR5 →
Q7F0R1	—	0.985	Q7F0R1 →
G5EF51	—	0.984	G5EF51 →
Q9STV0	—	0.984	Q9STV0 →
Q9FGY9	—	0.984	Q9FGY9 →
Q96BT7	—	0.984	Q96BT7 →
Q5XHF8	—	0.983	Q5XHF8 →
Q803R5	—	0.983	Q803R5 →
Q95K79	—	0.983	Q95K79 →
P31669	—	0.983	P31669 →
Q80Y20	—	0.983	Q80Y20 →
Q5RF63	—	0.983	Q5RF63 →
Q5U2Z5	—	0.982	Q5U2Z5 →
A2RUV5	—	0.982	A2RUV5 →
Q8N1G2	—	0.982	Q8N1G2 →
Q5E9U4	—	0.982	Q5E9U4 →
Q8BTI9	—	0.982	Q8BTI9 →
P42348	—	0.982	P42348 →
Q8VIJ5	—	0.982	Q8VIJ5 →
Q6GQ76	—	0.981	Q6GQ76 →
Q9DBC3	—	0.981	Q9DBC3 →
Q8GT06	—	0.981	Q8GT06 →
Q14AI0	—	0.981	Q14AI0 →